Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis <scp>C</scp>

Hu, Chih-Chien; Lin, Cheng‐Jui; Kuo, Y.-L.; Chien, Cheng‐Hung; Chen, S.-W.; Yen, Chieh-Li; Lin, Chien Yih; Chien, Rong‐Nan

doi:10.1111/apt.12112

Cited by 27 publications

(22 citation statements)

References 42 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One found lower rates of SVR in the elderly undergoing dual therapy. 28 The other found no difference in SVR between elderly and nonelderly undergoing triple therapy. 30 One study included genetic data, looking at the effect of the IL28B gene on SVR.…”

Section: December 15mentioning

confidence: 95%

“…After a manual review, 118 duplicates and 650 studies irrelevant to our objectives were excluded, and 134 studies remained for further screening. Applying the inclusion and exclusion criteria, a total of 19 studies (four randomized control trials [RCTs], [14][15][16][17] ten meta-analysis studies, [18][19][20][21][22][23][24][25][26][27] three nonrandomized intervention studies, [28][29][30] one cross-sectional study, 31 and one cohort study 32 ) were included for the updated studies for this review (Table 1). Additionally, eight RCTs were also included in this review that were published during the study period of Chou et al 13 and met the inclusion/exclusion criteria, but were not reviewed by them.…”

Section: Methodsmentioning

confidence: 99%

“…They found that SVR rate was significantly lower in the elderly than in the middle aged (40.7% vs 61.5%, P=0.005) with follow-up for 24 weeks after the completion of treatment. 28 Interestingly, the significant difference only occurred in nongenotype 1 HCV patients. Compared to the middle-aged group, the elderly had a significantly higher rate of anorexia, dyspnea, skin rash, and hematological adverse events, including thrombocytopenia and anemia.…”

Section: Studies Other Than Rcts Dual Therapymentioning

confidence: 97%

“…Hu et al 28 evaluated the efficacy and safety of weekly PEG-IFN plus RBV among middle-aged adults (50-64 years) compared to the elderly adults ($65 years) with chronic HCV infection in Taiwan. They found that SVR rate was significantly lower in the elderly than in the middle aged (40.7% vs 61.5%, P=0.005) with follow-up for 24 weeks after the completion of treatment.…”

Section: Studies Other Than Rcts Dual Therapymentioning

confidence: 99%

See 3 more Smart Citations

Current issues in comparative effectiveness research for hepatitis C

Yoo¹,

Yan²,

Rhien³

et al. 2014

CER

View full text Add to dashboard Cite

Background: With increasing treatment options for hepatitis C, evidence of comparative effectiveness of these treatment options is required to improve treatment outcomes. The purpose of this study was to evaluate the most recent comparative effectiveness research and suggest future directions for hepatitis C research. Methods: We identified and evaluated the literature on comparative effectiveness research and conducted a literature search for additional studies since the most current review. A review of ongoing clinical trials in hepatitis C was performed to assess how forthcoming research is addressing the research gaps and limitations. Results: Since a comprehensive comparative effectiveness research review by Chou et al new studies have been published, which were mostly consistent with the consensus in the literature. A few of them added to comparative effectiveness research knowledge by addressing issues of the likelihood of sustained virologic response in an older cohort, the effect of genomics and individualizing treatment duration, or the effect of delayed treatment. Research gaps and limitations of the existing comparative effectiveness research and future study needs were well identified in the second study from Chou et al. Some of the gaps and limitations were filled by additional research over the past year, though many of them still remained unanswered. Conclusion: To have complete information on the effectiveness of alternative treatments for hepatitis C virus, further research is needed on results in the general population, the effectiveness of treatment methods such as noninvasive treatment and individualized treatment, and the long-term effects of triple therapies. Additionally, evidence from a real-world setting is lacking. Methodologically thorough and independently funded retrospective research will help to generalize the effectiveness of current therapies for hepatitis C virus.

show abstract

Section: December 15mentioning

confidence: 95%

Section: Methodsmentioning

confidence: 99%

Section: Studies Other Than Rcts Dual Therapymentioning

confidence: 97%

Section: Studies Other Than Rcts Dual Therapymentioning

confidence: 99%

See 2 more Smart Citations

Current issues in comparative effectiveness research for hepatitis C

Yoo¹,

Yan²,

Rhien³

et al. 2014

CER

View full text Add to dashboard Cite

show abstract

“…HCV enfeksiyonu tafl›yan hastalar›n tedavisi ile ilgili olarak yurt d›fl›nda [25][26][27][28] ve yurdumuzda [29,30] yap›lan baz› ça-l›flmalarda da bizim sonuçlara benzer kal›c› virolojik yan›t oranlar› bildirilmifltir. Gedik ve arkadafllar›, [31] genel anlamda ribavirin ile birlikte kullan›lan farkl› interferonlar›n etkinliklerini karfl›laflt›rd›klar› bir araflt›rmada, HCV enfeksiyonu tafl›yan hastalarda kal›c› virolojik yan›t oran›n› klasik interferon grubunda %63, pegile interferon grubunda ise %73 olarak bulmufllard›r.…”

Section: Tart›flmaunclassified

Anti HCV seropozitif kişilerde moleküler HCV RNA test sonuçlarının değerlendirilmesi

Çelik¹

2013

Turk Aile Hek Derg

View full text Add to dashboard Cite

Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis

Zhou

Luo

Xiao

et al. 2013

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Treatment-related adverse events (AE) were more frequent in older patients treated by pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C (CHC), and most of them required dose reduction. A meta-regression analysis was conducted to explore the possible reasons for this occurrence. We searched MEDLINE, EMBASE, and Web of Science through May 2013, for clinical trials examining the safety of PEG-IFN plus RBV in elderly patients with CHC. Data were extracted for host, viral, and outcome information. Single-arm meta-analysis was performed to evaluate AE. Meta-regression analysis was conducted to explore predictors for dose reduction secondary to AE. Eighteen observational studies met the inclusion criteria. The overall incidences of AE were 61.3%. Dose reductions due to AE were 54.2%. In patients with genotype 1, the rate of sustained virological response (SVR) was 36.9%. In patients with genotypes 2 or 3, the rate of SVR was 72.8%. Patients with more dose reduction due to AE have a tendency toward a lower likelihood of obtaining SVR (coefficient:-0.529), especially for genotype 1 patients. Host factors (male gender, coefficient 4.403; higher body weight, coefficient 0.140; and advanced fibrosis stage, coefficient 1.582) and viral factors (HCV genotype 1, coefficient 2.279) have a significant impact on dose reduction due to AE. Some host and viral factors affected dose reduction due to AE. Increasing rates of fibrosis with age may play a role as a mechanism affecting dose reduction secondary to AE and SVR in different age groups.

show abstract

Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C

Abstract: SUMMARY BackgroundLimited data are available on the efficacy and safety of antiviral therapy in geriatric patients with chronic hepatitis C virus (HCV) infection.

Cited by 27 publications

References 42 publications

Current issues in comparative effectiveness research for hepatitis C

Current issues in comparative effectiveness research for hepatitis C

Anti HCV seropozitif kişilerde moleküler HCV RNA test sonuçlarının değerlendirilmesi

Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis

Contact Info

Product

Resources

About